Diagnostic and Prognostic Significance of Serum MiR-203 in Patients with Acute Myeloid Leukemia

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2020 Jan 15

PMID 31933972

Citations 3

Authors

Zhuanzhen Zheng

Gong Rong

Guoxia Li

Fanggang Ren

Yanping Ma

Affiliations

Soon will be listed here.

Abstract

MicroRNAs play important roles in the initiation and progression of acute myeloid leukemia (AML). This study aimed to detect serum miR-203 expression levels in AML and explore its potential clinical significance. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was performed to measure the serum miR-203 levels in 134 patients with AML and 70 healthy controls. The results demonstrated that serum miR-203 expression was significantly reduced in AML patients compared with healthy controls. Receiver operating characteristic curve (ROC) analysis revealed miR-203 could distinguish AML cases from normal controls. Low serum miR-203 levels were associated with worse clinical features, as well as poorer overall survival and relapse free survival of AML patients. Moreover, multivariate analysis confirmed low serum miR-203 expression to be an independent unfavorable prognostic predictor for AML. The bioinformatics analysis showed that the downstream genes and pathways of miR-203 was closely associated with tumorigenesis. Downregulation of miR-203 in AML cell lines upregulated the expression levels of oncogenic promoters such as CREB1, SRC and HDAC1. Thus, these findings demonstrated that serum miR-203 might be a promising biomarker for the diagnosis and prognosis of AML.

Citing Articles

Liquid biopsies and minimal residual disease in myeloid malignancies.

Allam S, Nasr K, Khalid F, Shah Z, Khan Suheb M, Mulla S Front Oncol. 2023; 13:1164017.

PMID: 37213280 PMC: 10196237. DOI: 10.3389/fonc.2023.1164017.

Dysregulated circulating miR-4429 serves as a novel non-invasive biomarker and is correlated with EGFR mutation in patients with non-small cell lung cancer.

Ruan M, Sun L, Qiu W, Dong Y, Fang C, Cui H Bosn J Basic Med Sci. 2022; 22(4):553-559.

PMID: 35167433 PMC: 9392976. DOI: 10.17305/bjbms.2021.6450.

The Potential Diagnostic Accuracy of Circulating MicroRNAs for Leukemia: A Meta-Analysis.

Zhang W, Zhang G, Gao S Technol Cancer Res Treat. 2021; 20:15330338211011958.

PMID: 33902358 PMC: 8085375. DOI: 10.1177/15330338211011958.

References

Zhang X, Zhang Y, Liu X, Fang A, Li P, Li Z . MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin. PLoS One. 2015; 10(11):e0143441. PMC: 4657877. DOI: 10.1371/journal.pone.0143441. View

Wang C, Wang X, Liang H, Wang T, Yan X, Cao M . miR-203 inhibits cell proliferation and migration of lung cancer cells by targeting PKCα. PLoS One. 2013; 8(9):e73985. PMC: 3769394. DOI: 10.1371/journal.pone.0073985. View

Greither T, Grochola L, Udelnow A, Lautenschlager C, Wurl P, Taubert H . Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2009; 126(1):73-80. DOI: 10.1002/ijc.24687. View

Wang N, Liang H, Zhou Y, Wang C, Zhang S, Pan Y . miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC. PLoS One. 2014; 9(8):e105570. PMC: 4139332. DOI: 10.1371/journal.pone.0105570. View

Zhao J, Lu Q, Zhu J, Fu J, Chen Y . Prognostic value of miR-96 in patients with acute myeloid leukemia. Diagn Pathol. 2014; 9:76. PMC: 3975266. DOI: 10.1186/1746-1596-9-76. View

Ru P, Steele R, Hsueh E, Ray R . Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. Genes Cancer. 2011; 2(7):720-7. PMC: 3218409. DOI: 10.1177/1947601911425832. View

Estey E . Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol. 2013; 88(4):318-27. DOI: 10.1002/ajh.23404. View

Zhu X, Er K, Mao C, Yan Q, Xu H, Zhang Y . miR-203 suppresses tumor growth and angiogenesis by targeting VEGFA in cervical cancer. Cell Physiol Biochem. 2013; 32(1):64-73. DOI: 10.1159/000350125. View

Tang X, Chen L, Yan X, Li Y, Xiong Y, Zhou X . Overexpression of miR-210 is Associated with Poor Prognosis of Acute Myeloid Leukemia. Med Sci Monit. 2015; 21:3427-33. PMC: 4644019. DOI: 10.12659/msm.894812. View

10.

Zhao G, Guo Y, Chen Z, Wang Y, Yang C, Dudas A . miR-203 Functions as a Tumor Suppressor by Inhibiting Epithelial to Mesenchymal Transition in Ovarian Cancer. J Cancer Sci Ther. 2016; 7(2):34-43. PMC: 4725318. DOI: 10.4172/1948-5956.1000322. View

11.

Chu S, Wang G, Zhang P, Zhang R, Huang Y, Lu Y . MicroRNA-203 suppresses gastric cancer growth by targeting PIBF1/Akt signaling. J Exp Clin Cancer Res. 2016; 35:47. PMC: 4791790. DOI: 10.1186/s13046-016-0323-1. View

12.

Tallman M, Gilliland D, Rowe J . Drug therapy for acute myeloid leukemia. Blood. 2005; 106(4):1154-63. DOI: 10.1182/blood-2005-01-0178. View

13.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

14.

Liu Y, Ren F, Rong M, Luo Y, Dang Y, Chen G . Association between underexpression of microrna-203 and clinicopathological significance in hepatocellular carcinoma tissues. Cancer Cell Int. 2015; 15:62. PMC: 4479344. DOI: 10.1186/s12935-015-0214-0. View

15.

Gregory T, Wald D, Chen Y, Vermaat J, Xiong Y, Tse W . Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol. 2009; 2:23. PMC: 2700131. DOI: 10.1186/1756-8722-2-23. View

16.

Saini S, Majid S, Yamamura S, Tabatabai L, Suh S, Shahryari V . Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis. Clin Cancer Res. 2010; 17(16):5287-98. DOI: 10.1158/1078-0432.CCR-10-2619. View

17.

Lowenberg B, Downing J, Burnett A . Acute myeloid leukemia. N Engl J Med. 1999; 341(14):1051-62. DOI: 10.1056/NEJM199909303411407. View

18.

Zhang Y, Zhou S, Yan H, Xu D, Chen H, Wang X . miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1. Sci Rep. 2016; 6:19995. PMC: 4742816. DOI: 10.1038/srep19995. View

19.

Liu S, Feng P . MiR-203 Determines Poor Outcome and Suppresses Tumor Growth by Targeting TBK1 in Osteosarcoma. Cell Physiol Biochem. 2015; 37(5):1956-66. DOI: 10.1159/000438556. View

20.

Obayashi M, Yoshida M, Tsunematsu T, Ogawa I, Sasahira T, Kuniyasu H . microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer. Oncotarget. 2016; 7(7):8223-39. PMC: 4884988. DOI: 10.18632/oncotarget.6972. View